Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
2(50.0%)
Phase 3
1(25.0%)
Phase 2
1(25.0%)
4Total
Phase 1(2)
Phase 3(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05697718Phase 1Completed

Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cells (IxCell hUC-MSC-S) in the Treatment of Ischemic Stroke

Role: lead

NCT07197606Phase 2Not Yet Recruiting

Clinical Trial of Umbilical Cord Mesenchymal Stem Cells in Subacute Ischemic Stroke

Role: lead

NCT06823063Phase 1Not Yet Recruiting

Clinical Trial of Human Umbilical Cord Mesenchymal Stem Cells (IxCell hUC-MSC-P) in the Treatment of CTD-ILD

Role: lead

NCT06716281Phase 3Recruiting

Efficacy and Safety of IxCell hUC-MSC-O in Patients With Knee Osteoarthritis

Role: lead

All 4 trials loaded